NCT02630693 2025-11-25Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast CancerCanadian Cancer Trials GroupPhase 2 Completed180 enrolled 14 charts